Please ensure Javascript is enabled for purposes of website accessibility

The FDA Needs a Bake Sale

By Brian Orelli, PhD - Updated Apr 5, 2017 at 7:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The agency needs a fundraiser more than anything.

Dear President-elect Obama,

Among the many other issues facing you, I have a suggestion for your selection of the new chief of the Food and Drug Administration. How about Brian Gallagher, the president and CEO of United Way, or maybe Yale's director of annual giving, Karri Brady?

Do they have a background in drugs or food? Not that I know of, but I'm sure they're both pretty good at raising money.

And money seems to be at the root of the problem with the FDA right now. It's pretty clear that PDUFA fees, even though they're up to over $1 million per marketing application, aren't enough to get things done in a timely manner.

Just take a look at some of the delays drugmakers have experienced this year with their marketing applications:

Drug

Company

Delay

Prasugrel

Eli Lilly (NYSE:LLY)

Original PDUFA at the end of June, but still no word on approval

Telavancin

Theravance (NASDAQ:THRX)

Original PDUFA date of July 21, but still no word on approval

Ranexa

CV Therapeutics (NASDAQ:CVTX)

Delayed over three months before approval

Stelara

Johnson & Johnson (NYSE:JNJ) and Medarex

Delayed three months before FDA asked for more information

Fablyn

Ligand Pharmaceuticals and Pfizer (NYSE:PFE)

PDUFA date pushed back three months to January 2009

Those delays result in real costs for the companies and patients. Not only do companies lose potential revenue while they wait, but it's a little hard to hit the ground running with marketing when you don't know when a drug will be approved. Further, patients are denied receiving potentially beneficial medications in a timely manner.

Yes, Mr. Obama, you could just hire a scientist and fund the agency at a reasonable level, but I know you've got better things to spend my tax dollars on, like bailing out the likes of General Motors (NYSE:GM) and Citigroup (NYSE:C). So please take my suggestion under advisement. Get someone in there who knows how to hold bake sales. That's the only way drug investors are going to get back to the old semi-predictable FDA that made investors some serious dough.

Sincerely,
Brian Orelli, Ph.D.
Foolish Drug Investor

Pfizer, Eli Lilly, and Johnson & Johnson are Motley Fool Income Investor recommendations. Pfizer is an Inside Value selection, and the Fool owns some shares. CV Therapeutics is a Rule Breakers pick. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., prefers cookies to cake. He doesn't own shares of any company mentioned in this article. The Fool's disclosure policy tastes better with milk.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$304.61 (0.53%) $1.59
Citigroup Inc. Stock Quote
Citigroup Inc.
C
$53.19 (2.11%) $1.10
General Motors Company Stock Quote
General Motors Company
GM
$37.95 (3.63%) $1.33
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$170.67 (0.29%) $0.49
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.95 (0.34%) $0.17
Gilead Palo Alto, Inc. Stock Quote
Gilead Palo Alto, Inc.
CVTX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.